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Overcoming Innovation Limits through Outward FDI: 
The Overseas Acquisition Strategy of Indian Pharmaceutical Firms 
 
Abstract: A host of strategic government policies including a process patent regime led to the 
rise of Indian pharmaceutical firms with significant process development capabilities. With 
policies getting liberalized overtime and a product patent regime in place, now firms’ survival 
crucially depends on their abilities to develop new products and brand creating exercise. Indian 
pharmaceutical firms with their inadequate product development capabilities are clearly at 
serious risk. In this context, an increasing number of Indian pharmaceutical firms are observed 
to be using acquisition as a strategy to overcome their limited innovation strength by accessing 
new products and their technologies, skills and new markets. Overseas acquisitions represent 
both challenges and opportunities for Indian pharmaceutical firms aspiring to emerge as global 
entities based on advance technologies.    
 
Keywords: Indian pharmaceutical industry; Outward FDI; Overseas Acquisition.  
 
 
1. Introduction 
 
India is among a few developing countries to succeed in building strong local capability 
in the technology-intensive pharmaceutical sector1. Presently Indian pharmaceutical industry has 
indigenous technological and productive capabilities to meet up to 70 per cent of the domestic 
requirement of bulk drugs and almost all the demands for formulations2. Its cost-effective 
technological capabilities not only restrict imports from developed countries into India, but also 
generate rising trade surpluses in pharmaceutical products by exporting to over 65 countries3. In 
a sense, India has emerged as a major developing country competitor in the world 
pharmaceutical market. 
With over 16000 pharmaceutical units, Indian pharmaceutical industry is one of the 
largest and most advanced among developing countries that produces life-saving drugs 
belonging to all major therapeutic groups at a fraction of prices existing in the world market. The 
industry today possesses the largest number of US Food & Drug Administration (USFDA) 
approved manufacturing facilities outside the US and has been filing more number of Drug 
Master Files (DMFs) with the USFDA for drug exports to the US than that filed by Spain, Italy, 
China and Israel taken together4.  
Considering the 1950s period when India hardly had any base in pharmaceutical sector, 
these achievements are truly remarkable for a developing country. The role of strategic 
government policies has clearly been critical in local technological developments that took place 
in Indian pharmaceutical industry. These government policies led the initial capability formation 
                                                          
1 China, Singapore, Korea, Czech Republic, Brazil, and Argentina are other developing countries that have 
important base in pharmaceutical sector. 
2 Department of Chemicals and Petrochemicals (2000), Annual Report 1999—2000, Ministry of Chemicals and 
Fertilizers, Government of India, New Delhi. 
3 Organization of Pharmaceutical Producers of India (2004), ‘Indian Pharmaceutical Industry – Fact Sheet 2004’, 
available at http://www.indiaoppi.com/keystat.htm  
4 Deccan Herald (2005), ‘Drug patent: A Viagra for Indian pharmaceutical industry’, April 4.  
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to produce modern drugs locally by establishing public-owned companies and allowed reverse 
engineering-based technological change for domestic private-owned companies.  
However, the setting of technological developments adopted by Indian companies was 
lopsided. Local innovation has been mostly limited to cost-effective process development and 
firm-specific R&D (Research & Development) strategy grossly neglected new product 
developments. While weaker intellectual property rights stimulated process innovation by Indian 
companies in the past but in subsequent period they emerged as an important obstacle to advance 
technological developments and learning. With globalization and liberalization, Indian 
pharmaceutical firms are increasingly forced into world market and their inadequate product 
development capabilities are likely to marginalize their future growth and expansion. In this 
backdrop, the role of outward FDI can be instrumental for Indian firms to overcome this 
particular limitation in their innovation strategy. Through overseas acquisitions Indian 
pharmaceutical firms can quickly enlarge their product portfolios and intangible asset bundle by 
adding new technologies, managerial and marketing skills. 
This paper has examined the ways by which outward FDI can help Indian 
pharmaceuticals firms to overcome their inadequate capabilities for product innovation. Section 
2 explores the main mechanisms through which India has built its technological base in the 
pharmaceutical sector and spell out how they have restricted innovation activities of Indian firms 
to just process developments. Besides considering the technological benefits that overseas 
acquisitions have on acquiring Indian pharmaceutical firms, Section 3 focuses on trends and 
geographical pattern of Indian pharmaceutical OFDI. It also presents a series of short case 
studies related to five largest acquirers from Indian pharmaceutical sector. These case studies 
primarily based on company annual reports, company press releases and newspaper reports seek 
to identify the main motivations of acquisitions that are available from managerial comments and 
perspectives. These case studies are to address the basic question of this paper: Are Indian 
pharmaceutical companies using overseas acquisition to overcome their limited product 
development technological capabilities? Section 4 concludes the paper. 
  
2. Developing local technological capability  
 
In the initial period during 1950s–60s, the Indian pharmaceutical industry was largely 
dominated by foreign enterprises and possessed hardly any local productive capability based on 
indigenous raw materials. Foreign firms, enjoying a strong patent protection under the Patent and 
Designs Act 1911, were averse to local production and mostly opted for imports from home 
country as working of the patent. The absence of domestic competition and product patent 
regime provided foreign firms with abnormal monopoly power to charge higher prices for their 
drugs. Foreign firms even with their shallow specialization centered on trading activities could 
reap extraordinary profits (Rs. 600 crore annual sales for an investment of less than a few crore!) 
(Joseph, 1979). Further, these foreign firms tend to operate in lucrative pharmaceutical segments 
rather than meeting demand for essential life saving drugs. While the existing product patent 
regime arrested the potential of local knowledge developments via incremental innovation, 
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general Indian population suffered most during this period under the consistent scarcity of 
essential medicines and surging drug prices. 
These adverse situations, namely inadequate technological capabilities of the domestic 
sector to start local production and hesitation of foreign firms to do so, called for active policy 
interventions and the Indian government decided to intervene through direct public sector 
investment. This led to the establishment of the Indian Drugs and Pharmaceuticals Ltd. (IDPL) 
plants at Rishikesh and Hyderabad in 1961 and the Hindustan Antibiotics at Pimpri, Pune, in 
1954 to manufacture penicillin. The starting of the public sector enterprises has been an 
important step towards scaling up indigenous technological capability of Indian pharmaceutical 
sector as they assumed the initiative in producing bulk drugs indigenously and led to significant 
knowledge spillovers on the domestic private sector. In addition, government has initiated 
building national institutions for creating scientific, managerial and general skills, which shall be 
readily and cheaply available to the industry for productive purposes. 
The positive role of direct public sector investment in local technological progress has 
been complemented by the enactment of the Indian Patent Act (IPA) 1970 and the New Drug 
Policy (NDP) 1978 in the 1970s. The IPA 1970 brought in a number of radical changes in the 
patent regime by reducing the scope of patenting to only processes and not pharmaceutical 
products and also for a short period of seven years from the earlier period of 16 years. It also 
recognizes compulsory licensing after three years of the granting of the patent. The enactment of 
the process patent regime contributed significantly to the local technological development via 
adaptation, reverse engineering and new process development (Aggarwal, 2007; Pradhan and 
Alakshendra, 2006). As there exists several ways to produce a drug, domestic companies 
innovated cost-effective processes and flooded the domestic market with cheap but quality drugs. 
This led to the steady rise of the domestic firms in the market place. The NDP 1978 has 
increased the pressure on foreign firms to manufacture bulk drugs locally and from the basic 
stage possible. Foreign ownership up to 74 per cent under the Foreign Exchange Regulation Act 
(FERA) 1973 was permitted to only those firms producing high technology drugs. Foreign firms 
that are simply producing formulations based on imported bulk drugs were required to start local 
production from the basic stage within a two-year period. Otherwise, they were required to 
reduce their foreign ownership holding to 40 per cent. New foreign investments were to be 
permitted only when the production involves high technology bulk drugs and formulations 
thereon. 
The outcome of the strategic government interventions in the form of a soft patent policy 
and a regime of discrimination against foreign firms affected the industry with a time lag and 
provided strong growth impetus to the domestic sector during 1980s. Domestic enterprises based 
on large-scale reverse engineering and process innovation achieved near self-sufficiency in the 
technology and production of bulk drugs belonging to several major therapeutic groups and 
developed modern manufacturing facilities for all dosage forms like tablets, capsules, liquids, 
orals and injectibles. These had a lasting impact on the competitive position of the domestic 
firms in the national and international markets. In 1991, domestic firms have emerged as the 
main players in the Indian market with about 70 and 80 per cent market shares in the case of bulk 
drugs and formulations respectively (Lanjouw, 1998). The industry turns out to be one of the 
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most export-oriented sectors in Indian manufacturing with more than 30 per cent of its 
production being exported to foreign markets (Pradhan, 2007). The trade deficits of the seventies 
have been replaced by trade surpluses during 1980s. 
Although the Indian policy regime has succeeded in building local capability in 
pharmaceutical sector but it has also created a number of limitations in pushing forward firm’s 
productivity and technological activities (Figure-1). It is noteworthy that Indian domestic 
pharmaceutical companies now have advantage of innovative cost-effective processes, discovery 
in novel drugs delivery system, self-reliance in producing quality raw materials and production 
led by quality management. However, these technological strengths are confined to a small 
group of large Indian pharmaceutical companies. Indian pharmaceutical industry hosts a total of 
16326 units of which just 123 units are large-sized (Pradhan and Sahu, 2008). Clearly, majority 
of the Indian pharmaceutical companies suffered from limitation of financial, technical and skill 
resources to undertake any kind of R&D activities. It is estimated that R&D-doing firms 
constitute about just 18 per cent among small pharmaceutical firms whereas they respectively 
account for 32 and 52 per cent among large- and medium-sized pharmaceutical firms during 
1991–2005. Notably, the R&D intensity of large firms has gone up significantly from 0.15 per 
cent in 1990–91 to 5.62 per cent in 2004–05 and that of medium and small pharmaceutical firms 
fluctuated below 1 per cent mark. 
 
Figure-1 A simplistic Perspective on Technological Capabilities of Indian Pharmaceutical 
Firms. 
 
 
 
Adding to the limitation of a small number of Indian pharmaceutical firms undertaking 
R&D is the fact that such R&D expenses are not only of minimal amount, but have also been 
predominantly for process technological activities. The process patent regime that remained in 
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place throughout 1972–2005 incentivized the process of technological change in a narrow range 
to improvements in production process, raw material and intermediate inputs. Indian companies 
had little inducement to undertake research for product developments as other Indian companies 
can legally launch any new product by simply resorting to another new process. As a result, 
firm-level capability in product developments was significantly undermined and for a long time.  
With cost-effective processes, Indian companies have focused on the low end of value-chains in 
pharmaceuticals like producing generics than opting for branded products or supplying bulk 
drugs to global players than market formulations of their own. Moreover, the fragmented 
domestic markets protected from external competition have actually ushered an era of price 
competition in the domestic market, which was essentially achieved via new cost-efficient 
process rather than the non-price competition based on quality and frontier innovation. Limited 
innovation or incremental innovation alone defines the criteria for firms’ survival and growth 
under the contemporary protected domestic market and process patent regime. 
However, the weakness of this limited innovation strategy for firm growth is quite 
obvious with the implementation of liberalization measures with regard to the Indian 
pharmaceutical industry like permission to 100 per cent inward FDI under automatic route and 
widespread import tariff reductions on pharmaceutical products and machinery. The competition 
faced by Indian pharmaceutical firms is increasingly globalizing with competitive sources 
shifting from low price advantage to those based on product innovation, quality, skill and 
product differentiation. The adoption of product patent regime by India in mid-2000s required 
that Indian firms now adopt new forms of innovation, i.e. product innovation if they like to 
survive. The growing competition also requires them to expand their market focus from local to 
overseas markets.  
         
3. OFDI to overcome innovation limits  
 
With markets and competition getting globalized, the innovation strategy of Indian 
pharmaceutical firms require a major transformation with increasing focus on quality and 
product development, which were hitherto neglected. They are urgently required to set up in-
house R&D centre and allocate substantial financial and skill resources for both process and 
product developments to face imminent competitive challenges. Such product-oriented R&D 
investments are not only risky, but also involve long gestation period with uncertain outcome. 
Apparently, the route of high cost in-house R&D for enlarging product portfolio is a suitable 
long-term technological strategy for Indian pharmaceutical firms but would obviously not serve 
their purpose of meeting imminent competitive pressures being unleashed by liberalizing 
policies.  
In this context, outward FDI can allow Indian pharmaceutical firms to overcome their 
most important innovation limit of inadequate product development capability. Indian firms 
rather putting their scare resources in long-term high-cost innovation strategy can simply acquire 
foreign companies with new product portfolio and advance technologies. Such strategic asset-
seeking OFDI immediately upgrade acquiring firms to a higher scale of technological 
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specialization and diversification and offer a way to overcome entry barriers that exist in 
accessing developed countries markets. Added to these positive spinoffs, acquiring Indian firms 
are likely to derive immediate market expansion, economies of technological and business 
synergies, and to access new marketing skills, overseas sales distribution networks, and 
organizational knowledge (Figure-2).  
 
Figure-2: Possible Effects of Outward FDI 
 
 
The physical presence of Indian companies through greenfield and brownfield OFDI in 
innovative developed countries also provide opportunities for considerable technological and 
organizational learning simply because of proximity to innovative competitors. Indian 
pharmaceutical firms can absorb knowledge-spillovers from large scale R&D activities that are 
actually going on in developed countries and global market pressures shall in turn keep them on 
the path of constant learning and technological improvements.  
Recently, a number of Indian firms are realizing that building sustainable competitive 
advantage in global markets requires more than just undertaking greenfield OFDI to exploit 
ownership advantages based on process technologies. Brownfield OFDI or acquisition is 
required to collect considerable knowledge on product developments and access trade-supporting 
infrastructure in foreign countries. As a result, they are now adopting an aggressive acquisition 
strategy with multiple firm-specific objectives like access to markets, products, technologies, 
marketing networks and to reap operating business synergies. Up to the end of 1990s, OFDI 
activities by Indian pharmaceutical firms have been largely in greenfield mode and since 2000 
such activities are increasingly dominated by overseas acquisitions. 
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3.1. Emergence of Indian pharmaceutical OFDI 
 
The emergence of Indian pharmaceutical OFDI can be traced back to two Nigerian joint 
venture OFDI projects undertaken by two Indian firms between 1977 and 1982—one established 
by Ranbaxy Laboratory Limited in 1977 and another by Unique Pharmaceutical Laboratories  in 
1982. Another four Indian companies, namely Ambalal Sarabhai Enterprises, Glenmark 
Pharmaceuticals, Lupin Laboratories and Hoechst India (a subsidiary of a German company) 
joined the OFDI process during 1983–89. Except one case of investment made by Ambalal 
Sarabhai Enterprises in UK, Indian pharmaceutical OFDI during 1977–1989 was confined to 
developing countries such as Nigeria, Malaysia, Nepal, Kenya, Indonesia and Thailand. The 
prevailing process technological advantages achieved by Indian pharmaceutical firms under the 
liberal patent regime appear to be the central force behind their OFDI activities.  They were 
motivated to exploit their ownership advantages based on cost-effective process innovation in 
other developing countries having liberal patent policies. 
With the growing process technological capability of Indian firms and off-patenting of 
many modern drugs since 1990, Indian pharmaceutical OFDI assumed greater scale and high 
degrees of geographical specialization in 1990s. A total of 61 Indian pharmaceutical companies 
undertook US $212 million worth of investment in 43 host countries in the 1990s (Table-1, 
Figure-3). Nearly 36 per cent of this aggregate investment has gone into developing countries. 
During this period a shift in the Indian policy regime occurred that allowed global competition 
into the pharmaceutical sector through inward FDI and imports of drugs. New competitive 
pressures in turn forced Indian pharmaceutical firms to expand their market focus and to improve 
their technological profile to include product development capability. The forthcoming product 
patent regime in 2005 and compulsory adoption of good manufacturing practices further 
diminished the traditional importance of process development capabilities in firms’ survival and 
growth strategy. This made Indian pharmaceutical firms more conscious about the importance of 
global markets and new sources of competitiveness like quality, product development 
capabilities and constant innovation in management system. 
The period 2000–07 witnessed a sharp rise in the size of outward Indian pharmaceutical 
investment led by an increasing number of Indian parent companies. Unlike in the past, a 
significant chunk of Indian pharmaceutical OFDI in early 2000s was to acquire new products 
and foreign knowledge to overcome existing limitations in their innovation strategy. From 
existing official sources, it is difficult to arrive at the magnitude of strategic asset-seeking OFDI 
in total pharmaceutical OFDI from India. The official statistics, among other limitations, capture 
only a part of total overseas acquisitions done by Indian firms (see Pradhan, 2008 for more 
detail). As the majority of overseas acquisitions concluded by Indian firms is led by substantial 
resource mobilization from overseas sources including foreign affiliates of Indian firms, Indian 
official sources only include a part of finance that Indian parent companies transfer from India to 
abroad for acquisition. Therefore, the estimated US $2.7 billion pharmaceutical outward FDI 
obtained from different official statistics has been termed as greenfield in Table-1. Given the 
imperatives of Indian pharmaceutical firms to expand their market size and acquire firm-specific 
assets, it is not surprising that overwhelmingly Indian pharmaceutical FDI during 2000–07 has 
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gone into innovative developed countries with large-sized pharmaceutical market. Developed 
region hosts as high as 88 per cent of Indian pharmaceutical FDI in this period. The relative 
significance of pharmaceutical OFDI in Indian manufacturing OFDI is also quite substantial for 
recent periods. Unlike pre-1990s period where Indian pharmaceutical firms contributed minimal 
amount, but have accounted remarkably higher share at 33 per cent in 2000–07 (Figure-3).      
 
 
Figure-3 Indian Pharmaceutical Greenfield OFDI, 1977–March 2007, In US $ million. 
 
Note & source: Same as Table-1 
 
 
           
Table-1 Trends of Indian Greenfield Pharmaceutical OFDI Flows, 1977–2007 
Period FDI Value (US $ Million) 
No. of Indian Investing 
Firms 
No. of Host 
Countries 
1970–79 0.3 1 1 
1980–89 4 5 7 
1990–99 212 61 43 
2000–07** 2662 121 47 
All Years 2878 158 57 
Note: * Data for 2001 is only from January to March, 2002 is from October to December and 2007 data is from 
January to March. 
Source: Calculation based on a dataset compiled from unpublished remittance-wise information from Reserve Bank 
of India, published reports of Indian investment centre and unpublished firm-level information from Ministry of 
Commerce.     
Table-2 presents a summary of trends in overseas acquisitions made by Indian 
pharmaceutical firms over 2000–March 2008 based on a dataset compiled from different sources. 
It can be seen that overseas acquisitions by Indian pharmaceutical firms is a recent phenomena 
that is gaining a substantial dimension in terms of value and number of acquiring Indian 
companies. The value of 105 overseas acquisitions done by a total of 43 Indian pharmaceutical 
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companies targeted at 28 countries stood at US $2.9 billion during 2000–2008. In terms of 
geographical focus, Indian pharmaceutical acquisitions spread across a total of 19 developed 
countries and 9 developing countries (Table-3). Developed region with 82.6 per cent share in 
total acquisition value is clearly the leading host location for these acquisition activities. Such 
concentration of Indian pharmaceutical acquisitions in developed region is indicative of the trend 
that Indian pharmaceutical firms were compelled to use acquisition as a strategy to overcome 
their prominent innovation limit, namely inadequate product development capabilities. Skill-
intensive and R&D-oriented developed countries are thus emerging as attractive destinations for 
Indian firms seeking new products and new markets.     
 
  Table-2 Overseas Acquisitions by Indian Pharmaceutical Firms, 2000–08 
Year 
Acquisition in US$ 
million In Number 
Value Acquisition deals 
Acquiring 
Indian firms 
Target 
countries 
2000 2 2 2 
2001 1 1 1 
2002 12.8 6 3 5 
2003 114.3 6 6 4 
2004 68 10 8 8 
2005 472.8 28 16 16 
2006 1359 28 20 13 
2007 773 19 15 13 
2008* 74 5 5 5 
All Years 2873.9 105 43 28 
Note: *- Data is from January to March. 
Source: Based on dataset constructed from different reports from newspapers, magazines and financial consulting 
firms like Hindu Business Lines, Economic Times, Financial Express, Business World, Grant Thornton India, etc. 
 
 
Table-3 Regional Pattern of Overseas Acquisitions by Indian Pharmaceutical Firms, 
2000–08 
Region/country 
Acquisition in US$ million In Number 
Value Acquisition deals Acquiring Indian firms 
 Developed region 2373.9 86 41 
Australia 17 4 4 
Belgium 279 3 3 
Canada 1 1 
Czech Republic 1 1 
Denmark 6 1 1 
France 86 3 3 
Germany 652 6 5 
Hungary 2 2 
Ireland 150 2 2 
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Israel 454 2 1 
Italy 2 4 3 
Japan 3 3 3 
Norway 1 1 
Poland 8 2 2 
Spain 66 4 3 
Sweden 1 1 
Switzerland 77 3 2 
UK 156.9 15 13 
USA 417 28 20 
 Developing region 500 19 11 
Argentina 1 1 
Brazil 36 5 3 
Bulgaria 7 1 1 
China 6 5 4 
Mexico 59 2 2 
Romania 321 1 1 
South Africa 70 2 2 
Thailand 1 1 
Venezuela 1 1 1 
 All Regions 2873.9 105 43 
Note & source: Same as Table-2. 
 
 
3.2. Cases of leading Indian acquirers 
 
Table-4 presents 13 leading overseas acquirers from Indian pharmaceutical industry. 
Most of these acquiring Indian firms are industry leaders in India. Their emergence and growth 
have co-evolved with numerous public policies to support the domestic sector like starting of 
public sector drugs companies, government research laboratories, adoption of process patent 
regime, fiscal incentives for indigenous R&D, etc. These firms through substantial knowledge 
creation in new process development outcompeted dominant foreign players to emerge as key 
players in the domestic market and to build their internationalization strength through exporting. 
With the implementation of new technological policy regime warranted by TRIPs in the 
home country and traditional export markets, these Indian domestic firms realized that their 
existing process-oriented technological capabilities are not adequate enough for meeting global 
competitive challenges. Three amendments to Indian Patent Act in 1999, 2002 and 2005 
respectively provided for the provision of exclusive marketing rights, extension of patent 
duration to 20 years with reversion of burden of proof from patentee to defendant in issues of 
process patent infringement, and introduction of product patent protection. 
In view of these changes in regulatory regime, the focus of leading Indian pharmaceutical 
firms started shifting from knowledge creation for new process to new product and brand. It is 
not surprising that these firms have chosen overseas acquisition as a strategy to achieve multiple 
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objectives of new markets and new products. The broad range of their acquisition activities 
involved product and brand acquisitions, world-class manufacturing facilities and taking over of 
companies with significant intangible assets like products and technologies. This strategic asset-
seeking objective of leading acquiring Indian firms can be seen from short cases of five 
individual companies, which are discussed below. 
 
3.2.1. Ranbaxy Laboratories Ltd5. 
 
Ranbaxy Laboratories is the most aggressive overseas acquirer from Indian 
pharmaceutical sector with 11 acquisition deals spread across 10 countries. The company was 
early to recognize the imperative of TRIPS regime and inadequacy of its process development 
capabilities accumulated under an inward-looking development strategy. In his message to the 
shareholders of the company, Mr. Tejendra Khanna, Chairman, Ranbaxy Laboratories 
emphasized this fact very clearly: 
 
“As we approach the WTO deadline of January 1, 2005, for aligning our domestic patent 
laws to conform to the TRIPS Agreement (Trade Related Intellectual Property Rights), it is 
clear that domestic pharmaceutical companies will have to rely more for their future growth 
on developing new products from their own research and development efforts and less on 
producing and marketing of reverse engineered drugs.” Pp. 2, Ranbaxy Annual Report 1999. 
 
Apart from undertaking necessary reorientation of its in-house research activities to 
include product development, Ranbaxy has used acquisition as a strategy to simultaneously 
access new products and new markets. In September 1995, it has acquired Ohm Laboratories 
with the basic objective of accessing latter’s advanced manufacturing capabilities and 
technological processes to create quality branded and generic OTC products. According to the 
company press release, this acquisition has offered “a comprehensive development scale up and 
manufacturing of a diversified line of over-the-counter and Rx generic pharmaceuticals6.” In 
April 2000, Ranbaxy Laboratories has acquired Bayer's German generic business portfolio that 
includes 20 marketed generic products with all their formulations. The acquisition of the fully 
automated manufacturing and packaging line facility with state-of-the-art testing and quality 
assurance capabilities from New York based Signature Pharmaceuticals Inc. in July 2002, 
provided Ranbaxy Laboratories’ access to advanced research and development capabilities for 
manufacturing and distribution of controlled substances. ‘Signature’s acquisition provides 
strategic platform to Ranbaxy’s US operations vis-à-vis liquid dosage forms” is what Dr. Brian 
Tempest, President, Pharmaceuticals, Ranbaxy Laboratories commented upon this acquisition. 
 
 
 
                                                          
5 Ranbaxy Laboratories is in the process of being acquired by Japanese company Daiichi Sanyo since June 2008. 
However, the rise of Ranbaxy Laboratories and its internationalization process until now represent the experiences 
of a domestic-owned Indian pharmaceutical company. 
6 Ranbaxy Press Release (2002), ‘Ranbaxy acquires liquid manufacturing facility from Signature Pharmaceuticals 
Inc. USA’, July 23,  
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Table-4 Selected Leading Indian Acquirers Based on Number of Acquisition Deals Conducted during 2000-08. 
Name of Acquiring 
Firm 
Value (US$ 
million) 
Number of 
acquisition deals 
Name of target 
countries Description of acquisition deals 
Ranbaxy Laboratories 
Ltd. 471 11 
Germany, South Africa, 
Spain, Belgium, USA, 
Spain, Japan, France, 
Romania, Italy 
Strategic stake or acquisition of Germany-based generic business of 
Bayer AG, South Africa-based Be-Tabs Pharmaceuticals, Spain-
based  Efarmes' generic products, Belgium-based Ethimed NV, 
manufacturing facility of US-based Signature Pharmaceuticals Inc, 
Mundogen generic business of GlaxoSmithKline, Japan-based 
Nihon Pharmaceuticals, generic business of Aventis SA, Romania–
based Terapia SA; unbranded generic business of Allen S.p.A, 
Veratide–the anti-hypertensive brand in Germany from P&G. 
Strides Arcolab Ltd. 23 9 
Brazil, Mexico, Italy, 
Venezuela, Italy, 
Australia, Norway, 
Poland 
Strategic stake or acquisition of 26 percent in Brazil-based 
Cellofarm Ltda, 51 percent in Brazil-based Infabra Industria 
Farmaceutica Brasileria Ltda, 52 percent in Mexico_based Solara 
S.A. De C.V., Italy-based Beltapharm S.p.A., Venezuela-based 
Biopharma, Italy-based Diaspa SpA, drug houses of Australia 
(Asia) Private Ltd., Norway-based Farma Plus, Poland-based sterile 
manufacturing facility. 
Glenmark 
Pharmaceuticals Ltd. 11 8 
South Africa, Brazil, 
Czech Republic, USA, 
Argentina, Ireland, 
Canada 
Strategic stake or acquisition of South Africa-based Bouwer 
Bartlett Pty Ltd., Brand Uno-Ciclo from Brazil-based Instituto 
Biochimico Indústria Farmacêutica Ltd., Brazil-based Laboratorios 
Klinger Do Bras, Czech Republic-based Medicamenta, USA_based 
Napo Pharmaceuticals Inc., Argentina-based Servycal SA, two 
FDA approved products from Ireland-based Clonmel Healthcare 
Ltd., two New biological Entities (NBE) from Canada-based 
Chromos Molecular Systems Inc. 
Sun Pharmaceutical 
Industries Ltd. 482 6 USA, Hungary, Israel 
Strategic stake or acquisition of US-based Able Laboratories, 
Israel-based Taro Pharmaceutical Industries Ltd., ICN CO Hungary 
Ltd., three brands from US-based Women's First Healthcare, 
Valeant Pharmaceuticals International's manufacturing facility 
(Ohio). 
Aurobindo Pharma Ltd. 23 5 China, Italy, UK, USA 
Strategic stake or acquisition of China-based Shanxi Tongling 
Pharmaceuticals and Shanghai Wide Tex Chemical Co Ltd., 
intellectual property and marketing authorisations in Italy from 
generic drug maker TAD, UK-based Milpharm Ltd., an USFDA 
compliant cGMP manufacturing facility in US. 
Dr Reddy's Laboratories 
Ltd. 683.8 5 
Germany, UK, Spain, 
Mexico, USA 
Strategic stake or acquisition of Germany-based Betapharm 
Arzneimittel GmbH, UK-based BMS Laboratories and its 
subsidiary Meridian Health Care, Spain-based Litaphar SA, Roche's 
Active Pharmaceutical Ingredients (API) business in Mexico, US-
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based Trigenesis Therapeutics Inc. 
Jubilant Organosys Ltd. 192 5 USA, Belgium 
Strategic stake or acquisition of US-based Hollister-Stier 
Laboratories, Belgium-based Pharmaceutical Services Incorporated 
NV and PSI Supply NV, US-based Target Research Associates Inc, 
US-based Trinity Laboratories Inc & its wholly owned subsidiary 
Trigen Laboratories Inc, a US generics company. 
Nicholas Piramal India 
Ltd. 31 4 UK, USA 
Strategic stake or acquisition of UK-based Avecia Pharmaceuticals, 
Dobutrex brand rights from US-based Eli Lily & Company in India, 
global inhalation anaesthetics (IA) business of UK-based Rhodia 
Organique Fine Ltd., Pfizer's drug making facility at Morpeth in 
UK. 
Wockhardt Ltd. 218.3 4 UK, Germany, USA, Ireland 
Strategic stake or acquisition of UK-based CP Pharmaceuticals, 
Germany-based Esparma Gmbh, US-based Morton Grove 
Pharmaceuticals, Ireland-based Pinewood Laboratories. 
Cadila Healthcare Ltd 35 3 France, Japan, Brazil 
Strategic stake or acquisition of Alpharma SAS France, Japan-
based Nippon Universal Pharmaceuticals Ltd., Brazil-based 
Quimica e Farmaceutica Nikkho do Brasil Ltda. 
Dishman 
Pharmaceuticals & 
Chemicals Ltd. 
80.8 3 Switzerland, UK 
Strategic stake or acquisition of Switzerland-based Carbogen 
AMC1S AG, Switzerland-based I03S of Bern, UK-based 
Synprotec. 
Matrix Laboratories Ltd. 263 3 Belgium, Switzerland, China 
Strategic stake or acquisition of Belgium-based Docpharma, 
Switzerland-based Explora Laboratories SA, China-based MCHEM 
Pharma Group. 
Natco Pharma Ltd.  3 USA 
Strategic stake or acquisition of assets of US-based Newark Drugs, 
US-based NICK's drug store, US-based SaveMart Pharmacy. 
Note & source: Same as Table-2. 
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In continuation of its acquisition strategy, Ranbaxy Laboratories entered into an 
agreement to buy France-based RPG (Aventis) SA along with its fully owned subsidiary, OPIH 
SARL, in December 20037. With this acquisition Ranbaxy Laboratories became the fifth largest 
generic player in France and got access to strong brand equity of the acquired unit and its strong 
product portfolio covering 52 molecules8. To further strengthen its product portfolio, Ranbaxy 
Laboratories acquired a generic product portfolio consisting of 18 products belonging to the 
Spanish pharmaceutical company Efarmes SA in June 2005. Ranbaxy Laboratories’ Regional 
Director for Europe, CIS & Africa, Mr. Peter Burema described the significance of this 
acquisition as follows: 
 
“The acquisition fortifies our presence in Spain while augmenting our existing product 
portfolio. With this strategic development, we will be able to provide a wide range of quality 
generics to meet the growing needs of patients in this part of the world9.”       
 
The year 2006 has been a watershed year for acquisition strategy of Ranbaxy 
Laboratories with as many as five overseas acquisitions. In March 2006, Ranbaxy Laboratories 
acquired Allen generic business from GlaxoSmithKline in Italy and one generic company each in 
Romania and Belgium. The product portfolio acquisition is a route to fast track growth in Italy 
with Ranbaxy Laboratories deriving strong advantages from product complementarities in the 
short term and catering to the business opportunities that will be thrown open by future patent 
expiries10. The acquisition of Terapia is an important strategy for acquiring new knowledge and 
strong market presence in Europe. The acquired unit had strong distribution and marketing 
network in the Romanian pharmaceutical market with a wide range of portfolio and new product 
pipeline, excellent R&D capabilities, world class in-house bioequivalence facilities and low cost 
manufacturing facilities. According to Mr. Malvinder Mohan Singh, CEO & Managing Director, 
Ranbaxy Laboratories:  
 
“Terapia represents exceptional value for our stakeholders. Within the Ranbaxy fold, it 
unleashes multiple synergies of product development, product flow, low cost manufacturing, 
proximity and access to high growth markets, in country presence and sound fundamentals 
while being EPS accretive to the group immediately. The transaction is compelling and 
furthers us on our path to becoming a top five global generic company11.” 
 
Ethimed NV—the acquired company is 10th largest generic company in Belgium with 
over 20 product registrations and a significant customer network12. Clearly, this acquisition has 
been to further strengthen the global position of Ranbaxy in generic space. In July 2006, 
                                                          
7 Ranbaxy Press Release (2003), Ranbaxy to acquire RPG (Aventis) in France to propel European expansion, 
December 13. 
8 Ranbaxy Press Release (2004), ‘Ranbaxy now fifth largest generic supplier in France’, January 05. 
9 Ranbaxy Press Release (2005), ‘Ranbaxy acquires generic product portfolio from Efarmes of Spain’, June 09. 
10 Ranbaxy Press Release (2006) ‘Ranbaxy to acquire the unbranded generic business of Glaxosmithkline in Italy’, 
March 27. 
11 Ranbaxy Press Release (2006), ‘Ranbaxy acquires leading Romanian pharma company Terapia for US $324M’, 
March 29. 
12 Ranbaxy Press Release (2006), ‘Ranbaxy acquires Ethimed in Belgium’, December 30. 
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Ranbaxy Laboratories has acquired the Mundogen generic business of GlaxoSmithKline (GSK) 
in Spain. Apart from consolidating Ranbaxy’s presence in the rapidly growing Spanish generic 
market, this acquisition intends to strengthen its product portfolio13. 
With a move to expand its South African presence, Ranbaxy Laboratories acquired Be-
Tabs Pharmaceuticals (Pty) Limited in December 2006.  The acquired entity ranked fifth in the 
South African generic market and is the largest manufacturer of Penicillin formulations with 
ownership of a portfolio of ethical and over-the-counter (OTC) solid-oral and liquid 
formulations. The strategic motivation behind this acquisition has been summed up by Mr. 
Malvinder Mohan Singh as follows: 
 
“The acquisition of Be-Tabs’ results in considerable synergies and further strengthens 
Ranbaxy’s foothold in South Africa. It reinforces our position by expanding our portfolio in a 
key market that is exhibiting strong growth potential. The move will help us to provide 
effective disease management solutions in support of the government’s objective to make 
healthcare affordable to a wider cross-section of the population14.” 
 
 
3.2.2. Strides Arcolab Ltd. 
 
With 9 overseas acquisition deals, Stride Arcolab is the second most aggressive acquirer 
from Indian pharmaceutical industry. By the late 1990s, Stride Arcolab has realized the 
inadequacy of its own process innovation strategy to meet new challenges of TRIPS-based 
technological regime and started putting substantial focus on product development paradigm. 
The CEO and Managing Director of the company, Mr. Arun Kumar, stated this changing 
technological strategy of the company in following manner: 
   
“In preparation for the future, we have embarked on an aggressive product development 
strategy. Our newly created state-of-the-art product development centre in Bangalore will 
enable us to launch newer products at shorter intervals enabling a large portfolio of products 
both in nutraceuticals and generics. Our process development centre in Mangalore will 
enable the speciality chemicals division in its cost-cutting endeavors and will provide cutting 
edge manufacturing and process technologies”. Stride Arcolab Annual Report, 1999, pp. 13. 
 
The underlying desire of the company to broaden its geographical operation and global 
manufacturing scale led it to consistently pursue the route of overseas acquisition. In October 
1999, the company acquired a soft gelatin capsule manufacturing plant in New Jersey, USA. 
This acquisition has added substantial manufacturing capabilities to allow Stride Arcolab to be a 
major player in the international soft gelatin market. In 2001–02, the company undertook a total 
of three foreign acquisitions targeted at Brazil and Mexico. It has acquired 52 per cent stake in 
Solara Farmaceutica to enter into the fast growing Mexican market. This acquisition provided 
access to a state-of-the-art commissioned manufacturing facility by Solara for tablet and 
capsules. The acquisition of 52 per cent strategic stake in Infabra Industria Farmaceutica, Brazil 
enables Stride Arcolab to get access to 48 product registrations belonging to Infabra. This 
                                                          
13 Ranbaxy Press Release (2006), ‘Ranbaxy to acquire the Mundogen generic business of Glaxosmithkline in Spain’, 
July 18. 
14 Ranbaxy Press Release (2006), ‘Ranbaxy Acquires Be-Tabs Pharmaceuticals, the 5th largest generics company in 
South Africa for USD 70 MN’, December 01. 
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acquisition along with the acquisition of 26 per cent in Cellofarm Ltda greatly expanded Stride 
Arcolab’s presence in the Brazilian pharmaceutical markets. 
After consolidating acquired overseas entities and integrating them with the company 
during 2003–2004, Stride Arcolab went for second round of M&A with acquiring three entities 
in 2005. Besides acquiring sterile manufacturing facility in Poland, it acquired Beltapharm in 
Italy and Biopharma in Venezuela. Mr. Arun Kumar expressed the importance of polish 
acquisition as follows:     
 
"The facility at Poland represents a unique opportunity for the company to establish a 
manufacturing presence in Central Europe as well as expand its portfolio and business of 
finished forms. The Polish facility will give easier access to Europe at a low operating cost. 
The site has an excellent team and adequate space to take up expansions at a very low 
incremental cost15."  
 
In addition to acquiring Drug Houses of Australia (Asia) Private Limited (DHA) in 2006, 
Strides Arcolab acquired Diaspa’s USFDA approved Italian fermentation facility and Norway-
based Farma Plus in 2007. Singapore-based DHA is a very old generics company with GMP 
certified manufacturing facility. Besides being one of the leading branded generics player in 
Singapore, the acquired entity has important presence in Malaysia and Hong Kong. This 
acquisition is a key strategy of Strides Arcolab to grow in these regional markets and to create a 
strong regional brand image16. The acquisition of Farma Plus—an emerging player of hospital 
products in the Scandinavian market—is more of a market entry strategy. However, the 
acquisition of Milan fermentation assets of Disapa is clearly a strategic move by the company, 
which Mr. Arun Kumar summed up as follows:  
 
"The acquisition will give us immediate access to a USFDA and EU approved facility with 
strong history of technology and fermentation skills. A significant part of Strides dosage form 
businesses are based on fermentation active pharmaceutical ingredients (APIs). Diaspa 
delivers the integration needs for us in this crucial space. We further intend to harness the 
existing customer base and product capabilities of Diaspa and aim to become a leading 
player in the fermentation space. We are also delighted with the strong technology and 
management bandwidth Diaspa brings along with this acquisition17". 
 
 
3.2.3. Glenmark Pharmaceuticals Ltd. 
 
The third largest overseas acquirer from Indian pharmaceutical sector is Glenmark 
Pharmaceuticals with a total of 8 acquisition deals. The company was very early to appreciate 
the role of acquisition in creating essential capabilities for the challenges thrown up by product 
patent regime and global competition. The 1999–2000 Annual Report of the company explicitly 
mentioned acquisition as a potential growth strategy: “In its onward growth, Glenmark will 
continue to consider appropriate company and brand acquisition opportunities to enhance its 
portfolio” (pp. 8). 
Its first overseas acquisition was the Brazil-based Laboratorios Klinger in April 2004.  
                                                          
15 Hindu Business Line (2005), ‘Strides Arcolab to buy Polish co, take 70 pc stake in Italian venture’, August 02. 
16 http://www.domain-b.com (2006), ‘Strides Arcolab to acquire drug unit in Singapore’, September 01. 
17 Business Standard (2007), ‘Strides Arcolab to acquire Diaspa's Milan unit’, May 29. 
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The acquired entity had 21 approved product registrations in Brazil covering braded generics and 
OTC products. This acquisition was overwhelmingly a market entry strategy into the largest 
pharmaceutical market in South America and to quickly enhance market presence. In August 
2004, Glenmark acquired two FDA approved products from Clonmel Healthcare Ltd. As per 
Jeffrey Weiss, CEO, Glenmark Pharmaceutical Inc, this acquisition will accelerate Glenmark’s 
product growth plan in the US18. In March 2005, it acquired the exclusive manufacturing and 
marketing global rights of a leading hormonal brand, Uno-Ciclo from Instituto Biochimico 
Indústria Farmacêutica Ltda. Mr. Glenn Saldanha, Managing Director and CEO of Glenmark 
Pharmaceutical further emphasized this product acquisition strategy as:  
 
“The purchase of Uno-Ciclo is another step towards enhancing our product basket and 
extending our reach in Brazil and the Latin American region”.   
 
The acquisition of Servycal SA—an Argentine marketing company with a basket of 17 
approved product registrations and additional three products pending registration—in October 
2006 represent Glenmark’s direct entry strategy into Argentina. Apart from accessing Servycal’s 
strong retail and hospital presence in Argentina, this acquisition enhances Glenmark’s 
geographical presence in 12 other South American country markets where Servycal’s products 
are registered19. To further expand its geographical spread and width of product offerings, it has 
acquired Bouwer Bartlett Pty—a South African sales and marketing company in December 
2005.  Mr.  Glenn Saldanha offered following comment on this acquisition20: 
 
“The purchase of Bouwer Bartlett is part of our long-term strategy to emerge as a 
speciality/brand company marketing novel drugs, by acquiring front-ends in key markets 
outside the USA, the EU and Japan.” 
 
The year 2006 saw Glenmark acquiring new product than acquisition of companies or 
manufacturing assets. To accelerate its product-focused generics presence in the US market, 
Glenmark acquired manufacturing and marketing rights of 2 liquid generic pharmaceutical 
products from Lehigh Valley Technologies Inc. and another 3 generic controlled-substance 
pharmaceutical products from Aspen USA Inc. in May 2006. Another 7 products of Lehigh 
Valley Technologies targeted at the US market were acquired by the company in December 
2006. In June 2006, it has acquired global intellectual property rights of 7 products and 11 
presentations from P D Pharmaceuticals (Pty), South Africa. 
In March 2007, Glenmark acquired the company Medicamenta to get its first commercial 
foothold into the strategically important market of Europe. The acquitted entity with its basket of 
29 products has significant branded presence and strong sales and marketing operations in both 
Czech Republic and Slovakia. The President of Glenmark Europe, Guy Clark, while describing 
                                                          
18 Gleenmark Press Release (2004), ‘Glenmark Pharmaceuticals Inc., USA, acquires ANDAs from Clonmel Inc. and 
files its first complete Para 3 ANDA in the US’, August 30. 
19 Gleenmark Press Release (2005), ‘Glenmark acquires Servycal S. A., a marketing company in Argentina’ October 
26. 
20 Gleenmark Press Release (2005), ‘Glenmark acquires Bouwer Bartlett Pty. Ltd., a sales and marketing company 
in South Africa, December 26. 
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this acquisition has stated: 
 
 “This is the first of many steps that Glenmark will take on its journey to build a significant 
branded presence in the important market of Europe, and Medicamenta will also provide a 
geographically central base to support Glenmark’s other European distribution activities.” 
  
In July 2007, Glenmark acquired two new biological entities (NBE) from Canada-based 
Chromos Molecular Systems Inc to expand and diversify its product portfolio. 
 
  
 
3.2.4. Sun Pharmaceutical Industries Ltd. 
 
By 1990s, Sun Pharmaceutical with its strategy of serving niche high-margin market 
segments such as psychiatry and central nervous system drugs gained a good presence in the 
domestic market. The second half of 1990s witnessed Sun Pharmaceutical adopting a series of 
domestic acquisition to enlarge its product range and manufacturing capacity to emerge as a 
national player. After achieving rapid expansion in national market, Sun Pharmaceutical saw the 
emerging generics opportunities in the US and decided to extend its acquisition strategy to cover 
this overseas market. 
Caraco Pharmaceutical Laboratories—a Detroit based manufacturer of generic 
pharmaceuticals is the first overseas acquisition made by Sun Pharmaceutical. This acquisition 
was an entry strategy into the lucrative US generics market and was completed in successive 
equity stake enhancement in 1997, 2002, 2003 and 2004.  Sun Pharmaceutical viewed Caraco as 
a vehicle to get USFDA approval for its own generic products in the US and market introduction. 
The acquisition of three niche brands from the US-based Women's First Healthcare in September 
2004, marked Sun Pharmaceutical’s initial attempt in the US branded generic space. In 2005, it 
has acquired Valeant Pharmaceuticals’ Ohio manufacturing facility and US-based Able 
Laboratories. The Ohio manufacturing facility is expected to help Sun Pharmaceutical in reaping 
emerging opportunities in liquids and semi-solids like creams and ointments and in speeding up 
filings for the US generic market. By acquiring the rights to entire product line that were being 
marketed by Able Laboratories and its dosage-form manufacturing facilities, Sun Pharmaceutical 
has significantly expanded its US operation. 
Sun Pharmaceutical expanded its global manufacturing base by acquiring Hungary-based 
Valeant’s raw materials and dosage-form manufacturing operations in August 2005. This 
became Sun Pharmaceutical’s first European manufacturing base. In May 2007, it entered into 
definitive agreements to acquire Israel-based Taro Pharmaceutical Industries with established 
subsidiaries, manufacturing facilities and products across the US, Canada, Israel and Ireland. The 
acquired entity has strong product baskets in dermatology, cardiovascular, neuropsychiatric and 
anti-inflammatory therapeutic categories and possesses world-class manufacturing facilities with 
necessary regulatory approvals in operating markets. In the US market it has more than 100 
ANDA (Abbreviated New Drug Application) approvals from USFDA with additional 26 
ANDAs awaiting approval. By July 2008, Sun pharmaceutical has already acquired 36 per cent 
stake in Taro and has initiated a hostile bid to acquire additional 12 per cent stake from 
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controlling shareholders in July 2008.  
 
 
3.2.5. Dr. Reddy's Laboratories Ltd. 
 
For Dr. Reddy’s Laboratories, acquisition and consolidation is a means of improving 
R&D performance and enlarging the scale required to meet emerging hyper competitive market 
environment. The 1999–2000 Annual Report of Dr. Reddy’s Laboratories make this point very 
clear: 
 
“Worldwide, pharmaceutical companies are under pressure to consolidate–largely driven by 
the need to fund innovative R&D while gaining critical mass. The consolidation activity at Dr. 
Reddy's Laboratories in 1999-2000 echoes this global trend. The merger of group company, 
Cheminor Drugs with the flagship and the acquisition of American Remedies were moves in 
this direction. The unified company has emerged as India's third largest pharmaceutical 
player with revenues expected to reach Rs. 1000 crores in the financial year 2000-01.  
 
The competencies of Dr. Reddy's Laboratories now cover the entire pharmaceutical value 
chain from basic research to bulk actives to branded formulations and generics, and on to 
emerging areas such as custom chemical synthesis, diagnostics and biotechnology. Further it 
has helped the company acquire a global reach, with presence in all major world markets and 
form an extensive product portfolio.” (pp. 9). 
 
Having experimented with acquisitions within the national boundary, Dr. Reddy’s 
Laboratories begin to explore the advantages of acquisition strategy in overseas markets. In April 
2002, Dr. Reddy’s Laboratories went for its first overseas acquisition and acquired BMS 
Laboratories and its subsidiary, Meridian Healthcare UK Limited. The acquired group had two 
fully-integrated manufacturing facilities and is currently marketing more than 30 generic 
products and possessing another 70 product licenses. Mr. GV Prasad, CEO, Dr Reddy's 
Laboratories, put below his vision behind this acquisition: 
 
“This acquisition is a key step in our efforts to globalise our business. It gives us entry into the UK generics 
market through the BMS Group's established product basket and strong marketing network. We expect it to 
jumpstart our generics business in UK21.” 
 
In May 2004, Dr. Reddy’s Laboratories acquired US-based Trigenesis Therapeutics, Inc 
mainly to access latter’s proprietary drug delivery technology platforms in the dermatology 
segment. According to Mr. GV Prasad, this acquisition is an important element of the overall 
corporate strategy being followed by Dr. Reddy’s Laboratories to emerge as a specialty 
pharmaceutical company focused on the US market. While commenting on this acquisition, he 
said:  
 
“This deal provides us an exciting opportunity to apply various proprietary drug delivery 
technologies in creating a pipeline of differentiated drugs that will broaden the range of 
                                                          
21 Dr Reddy Press Release (2004), ‘Dr Reddy's signs definitive agreement to acquire BMS Laboratories and 
Meridian Healthcare UK’, March 12. 
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available treatment options and establish Dr. Reddy's in the prescription dermatology 
segment22." 
 
The upgradation of global scale, geographical spread and product diversification through 
acquisition by Dr. Reddy’s Laboratories continued even more strategically. The acquisition of 
Roche’s API business in November 2005 marked Dr. Reddy's Laboratories’ inclination to 
acquire new innovative capabilities in the API (Active Pharmaceutical Ingredient) space and 
custom pharmaceutical services. Mr. GV Prasad provided the following rationale for this 
acquisition: 
 
“With the acquisition of Roche’s API business at the Mexico site, Dr. Reddy’s will emerge as 
a leading player in Custom Pharmaceutical Services (CPS) business and position itself as a 
partner of choice for Innovator Companies across the globe with service offerings spanning 
the entire value chain of pharmaceutical services. This strategic acquisition provides an 
opportunity for our CPS business to grow from the current base of USD10 million to USD100 
million over the next 18 months. The integration of these businesses - people and technology; 
the expertise of the management team and distinctive manufacturing capability at the Mexico 
site, with that of Dr. Reddy’s strengths in process chemistry and world class research 
capabilities will provide a strong foundation to drive the next wave of growth in our CPS 
business23.” 
 
In 2006, Dr Reddy’s Laboratories acquired Betapharm Arzneimittel GmbH in Germany 
and Litaphar S.A in Spain. The acquisition of Betapharm—the fourth-largest generics company 
in Germany—provides ample evidence to the fact that Dr Reddy’s Laboratories’ overseas 
acquisition strategy has matured considerably. The acquisition of Betapharm, which operates on 
high-quality generic drugs with high prescription rates and a strong track record of successful 
product launches, is a logical strategy for Dr Reddy’s Laboratories to consolidate its global size 
and fostering technological developments. This acquisition immediately provided Dr Reddy’s 
Laboratories a critical size in Europe, a leading market position and a portfolio covering 145 
marketed products. The strategic benefits that have driven this acquisition can be seen from what 
Mr. GV Prasad had said: 
    
 "We are very excited with our strategic investment in betapharm. betapharm with its 
differentiated business model has all the key elements for achieving success in the fast 
growing generics market in Germany. We strongly believe that this strategic investment will 
generate substantial opportunities for long-term value creation for both the companies. The 
combination of these two companies will enable betapharm to continue to expand its growth 
trajectory and at the same time provide a strong foundation to leverage Dr. Reddy’s global 
product development and marketing infrastructure to build a significant generics business in 
Europe in the long-term. We are excited to partner with the highly dedicated and motivated 
team at betapharm to build a future of growth and leadership for Dr. Reddy’s as well as 
betapharm24." 
  
                                                          
22 Dr Reddy Press Release (2002), ‘Dr. Reddy's acquires access to Drug Delivery Technology Platforms in the 
Dermatology Segment:  Marks Company's foray into the $6 billion niche dermatology segment in the US’ May 06. 
23 Dr Reddy Press Release (2005), ‘Dr. Reddy’s signs definitive agreement to acquire Roche’s API business at its 
Mexico facility’, November 08. 
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In May 2006, Dr Reddy’s Laboratories acquired marketing authorizations and marketing 
authorization applications for certain specialty pharmaceutical products, along with the related 
trademark rights and physical inventories from Laboratorios Litaphar in Spain. Very recently, it 
has engaged in three overseas acquisition deals—Dowpharma Small Molecules business 
associated with Dow’s Mirfield and Cambridge in UK, BASF’s pharmaceutical contract 
manufacturing business and related facility in Shreveport, Louisiana, USA and an Italian 
company, Jet Generici Srl—all in April 2008. The Italian acquisition provided Dr Reddy’s 
Laboratories’ access to an essential product portfolio, a pipeline of registration applications, and 
a sales and marketing organization25. Following rationales were offered by the company 
managers behind the UK and US acquisition: 
 
 “The proprietary chiral and biocatalysis technology at the Cambridge site and the scale up 
capability in the Mirfield site will add significant value to the company. This acquisition will 
also bring strengths in industrial synthesis of complex prostaglandins and carbohydrate 
chemistry. These newer capabilities will add to our existing R&D and commercial 
infrastructure to position Dr. Reddy’s as a leading provider of Custom Pharmaceutical 
Services globally26.” Satish Reddy, Managing Director & Chief Operating Officer, Dr. 
Reddy’s Laboratories 
 
“We are excited about this acquisition as this facility provides us with a profitable revenue 
base built on strong customer relationships with branded and generic companies. It also 
provides us with an additional platform to further expand our portfolio of prescription 
generics, OTC capabilities and product portfolio and the ability to supply generic products to 
US government agencies27.” Mark Hartman, President, North America Generics, Dr. Reddy’s 
Laboratories. 
 
Clearly, the foregoing brief reviews on the experience of selected Indian pharmaceutical 
companies do indicate that they are using overseas acquisitions to expand their global market 
presence in addition to getting access to new products, marketing and managerial skills, and 
quality standards. With this newly gained knowledge they are expected to overcome their 
existing innovation barrier such as small size of their product portfolio primarily nurtured 
through process technological activities in the home country. In case these Indian pharmaceutical 
firms are able to integrate acquired new knowledge and efficiently absorb them for further 
knowledge developments, this overseas acquisition wave from India will have profound effects 
on both home and host countries. India will witness the emergence of truly global Indian firms 
based on advance knowledge and host countries are likely to benefit from supply of cost-
effective life-saving drugs and generics by Indian companies. 
 
 
                                                                                                                                                                                           
24 Dr Reddy Press Release (2006), ‘Dr. Reddy’s signs definitive agreement with 3i for the strategic acquisition of 
Betapharm’, February 16. 
25 Dr Reddy Press Release (2008), ‘Dr. Reddy’s acquires Jet Generici Srl. Acquisition to establish Generics business 
in Italy’, April 03. 
26 Dr Reddy Press Release (2008), ‘Dr. Reddy’s signs definitive agreement to acquire Dowpharma Small Molecules 
business associated with Dow’s Mirfield and Cambridge, UK Sites’, April 01. 
27 Dr Reddy Press Release (2008), ‘Dr. Reddy’s Acquires BASF’s Pharmaceutical Contract Manufacturing Business 
and related facility at Shreveport in the US’, April 30. 
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4. Concluding Remarks 
 
Initial constraints of being a developing country and non-existent productive base in 
modern pharmaceutical sector notwithstanding, India could build a very competitive 
pharmaceutical industry. The strategic government policies including public sector drug 
production, adoption of short duration process patent regime and strong monitoring of activities 
of foreign companies, resulted in significant growth of domestic investment in the 
pharmaceutical sector and increased local technological activities mainly in the form of cost-
effective process development. This led to rising domestic productive capacity to satisfy growing 
demand for drugs and prompted a consistent export surge to overseas markets. 
It is since 1990s the issue of a broad-based innovation strategy for long run growth of 
Indian pharmaceutical firms started attracting corporate and expert attention. The liberalization 
measures and a product patent regime made it imperative that Indian pharmaceutical firms must 
enlarge their innovation strategy towards product oriented R&D. Indian pharmaceutical firms 
without enhancing in-house capabilities to enlarge product portfolio are going to face more 
survival challenges in coming years. Many capable Indian pharmaceutical companies are early to 
realize these challenges and have gone for suitable measures like putting more resources for 
product and process development. In addition, they have also opted for overseas acquisition as a 
favourite strategy to overcome their inadequate product development and other intangible 
capabilities. Thus, the recent boom in overseas acquisitions by Indian pharmaceutical firms 
represents the strategic motivation of acquiring new products, new markets, skills and 
technologies. Brief case studies of five acquirers from Indian pharmaceutical sector further 
testify the desire of Indian companies to improve their competitive advantages by accessing new 
technologies and products. In this sense overseas acquisition can be seen as a means of 
overcoming limited product development capabilities that characterizes majority of Indian 
pharmaceutical companies.  
Although overseas acquisition can be important for enhancing firm-specific technological 
capabilities and for entering into new markets, they are also challenging for acquiring Indian 
pharmaceutical firms in a number of ways. Investment requirements in acquisition are quite 
substantial and not all Indian pharmaceutical firms have access to such resources. Especially, 
small- and medium-sized pharmaceutical units that dominate the Indian pharmaceutical industry 
shall not be able to benefit from the acquisition strategy. They don’t have financial, 
technological and skill resources to undertake overseas acquisition to improve their product 
portfolio. Therefore, the scope and opportunities that are associated with acquisition strategy are 
limited to relatively large Indian pharmaceutical companies. 
Since Indian pharmaceutical companies are new to global production, overseas 
acquisition involves significant market and operational risks. In the preparatory stage, the 
challenge is to decide on target markets and to identify target companies that can fit well into the 
requirements of Indian acquiring companies. In addition, Indian firms are required to determine 
the transaction value, negotiate with potential target companies and obtain information related to 
host country legal and environment clearances. Although financial accounting and consultancy 
firms help in these efforts, Indian firms should have adequate in-house skills to manage these 
issues more realistically. Insufficient knowledge of host country laws, regulatory delays, strong 
legal monitoring in host developed countries related to manufacturing process and quality of 
drugs and unexpected changes therein, rapid changes in demand and prices, growing 
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competition, etc., represents high risk entail in overseas acquisition.  
After acquisition, an Indian firm faces operational challenge to carry forward acquired 
production activities in foreign countries. The immediate issue is the post-acquisition integration 
that addresses the theme of harmonizing different work cultures, managerial practices, 
employment policies, etc., to successfully integrate the acquired overseas units and put it to 
efficient production. The scope for absorbing newly acquired foreign knowledge and benefiting 
from scale expansion clearly depends on the technological capabilities of acquirers themselves. 
It is clear that without a well designed acquisition strategy, acquiring Indian 
pharmaceutical companies may not realize intended benefits from such activities. As long as 
Indian acquiring firms are aware of the potential risks involved in acquisition and well prepared 
to face such eventualities, overseas acquisitions can contribute to their greater geographical and 
economic diversification and upgrading of their technological capabilities significantly. 
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